Heart failure & cardiomyopathies
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and Heart Failure with Preserved Ejection Fraction (HFpEF) on SGLT2 Inhibitors
Authors' conclusion
GLP-1 RA, in addition to SGLT2i, was associated with a significantly lower risk of heart failure hospitalizations in this patient population, suggesting a potential incremental benefit.
Study context
- Population
- Patients ≥18 years with T2DM, BMI ≥27 kg/m² and HFpEF on SGLT2i7,044 per cohort after matching
- Participants
- 7,044 vs 7,044
- Exposure
- GLP-1 RA plus SGLT2i vs SGLT2i only
- GLP-1 RA plus SGLT2in = 7,044
- SGLT2i-onlyn = 7,044reference
- Outcome
- HF exacerbation, all-cause ED visits/hospitalizations among others
- Follow-up
- 12 months
Methodological detailspropensity-score matched, TriNetX research database
- Propensity-score matched
- TriNetX research database
Main finding
As reported in the abstract
HF exacerbation, all-cause ED visits/hospitalizations, new-onset atrial arrhythmias, new-onset AKI, pulmonary hypertension
- Significantly lower risk of HF exacerbations, all-cause ED visits/hospitalizations, new-onset atrial arrhythmias, new-onset AKI and pulmonary hypertension with GLP-1 RA plus SGLT2i vs SGLT2i only
- Propensity score matched
Observational data: associations, not effects.
Further findings
Subgroups by BMI, EF and elevated natriuretic peptide
- Associated benefits persisted across BMIs and EFs and with elevated natriuretic peptide
Safety
Diabetic retinopathy
- Higher risk with combination therapy than with SGLT2i only
Original publication
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart Fail. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →